PTGS2 and acute kidney injury: Our findings are concordant with those of previous meta-analysis7 of randomized controlled trials of COX-2 inhibitors and showed that only rofecoxib was associated with elevated risk of AKI, but no such association was observed for other COX-2 inhibitors.